

## PE anti-human IL-10 Antibody

<b>Catalog# / Size</b>	506804 / 100 tests
<b>Clone</b>	JES3-19F1
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	Interleukin 10, B cell derived T cell growth factor (B-TCGF), Cytokine synthesis inhibitory factor (CSIF), T-cell growth inhibitory factor (TGIF)
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRF1. The biological activities of IL-10 include inhibition of macrophage-mediated cytokine synthesis, suppression of the delayed type hypersensitivity response, and stimulation of the Th2 cell response, which results in elevated antibody production. The JES3-19F1 antibody reacts with human and viral interleukin-10 (IL-10). The JES3-19F1 antibody can neutralize the bioactivity of natural or recombinant IL-10.

### Product Details

<b>Verified Reactivity</b>	Human
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	COS-expressed recombinant human IL-10
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">ICFC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">intracellular immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
<b>Excitation Laser</b>	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
<b>Application Notes</b>	<p><b>ELISA or ELISPOT Capture<sup>1-4</sup>:</b> The Purified JES3-19F1 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated JES3-12G8 antibody (Cat. Nos. 501502 &amp; 501503) as the detecting antibody. The Ultra-LEAF™ Purified antibody is suggested for ELISPOT capture. For use as an ELISPOT capture antibody, a concentration range of 4.0 - 8.0 µg/ml is recommended.</p> <p><b>Flow Cytometry:</b> The fluorochrome-labeled JES3-19F1 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-10 -producing cells within mixed cell populations. For intracellular cytokine staining protocol, please visit <a href="http://www.biolegend.com">www.biolegend.com</a> and click on the support section.</p> <p><b>Neutralization<sup>1,2</sup>:</b> The Ultra-LEAF™ Purified antibody (Endotoxin &lt;0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of human IL-10 bioactivity (Cat. Nos. 506814 &amp; 506815).</p> <p><b>Additional reported applications (for the relevant formats) include:</b> Western blotting, immunohistochemical staining<sup>5,6</sup> of paraformaldehyde-fixed, saponin-treated frozen tissue sections, and immunocytochemistry.</p> <p><b>Note:</b> For testing human IL-10 in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430601 to 430606) are specially developed and recommended.</p>

#### Application References

(PubMed link indicates

1. Abrams J, *et al.* 1992. *Immunol. Rev.* 127:5.
2. Gotlieb W, *et al.* 1992. *Cytokine* 4:385.

- BioLegend citation)**
3. Yssel H, *et al.* 1992. *J. Immunol.* 149:2378.
  4. Burdin N, *et al.* 1993. *J. Exp. Med.* 177:295.
  5. Andersson U, *et al.* 1999. *Detection and quantification of gene expression.* New York: Springer-Verlag.
  6. Andersson J, *et al.* 1994. *Immunology* 83:16.

#### Product Citations

1. de Jonge K *et al.* 2019. Scientific reports. 9(1):4487 . [PubMed](#)
2. Boyle M, *et al.* 2015. *J Infect Dis.* 212: 416-425. [PubMed](#)
3. Piao HY, *et al.* 2022. *J Exp Clin Cancer Res.* 41:174. [PubMed](#)
4. Shey M, *et al.* 2014. *J Immunol.* 192:4833. [PubMed](#)
5. Cerny V, *et al.* 2021. *Cent Eur J Immunol.* 45:393. [PubMed](#)
6. de Jonge K, *et al.* 2021. *OncoImmunology.* 10(1):1873585. [PubMed](#)
7. Liu Y, *et al.* 2015. *J Immunol.* 194:5851. [PubMed](#)
8. Zischke J, *et al.* 2017. *PLoS Pathogens.* 13(6):e1006454. [PubMed](#)
9. Zarobkiewicz M, *et al.* 2020. *Cancers (Basel).* 12:00. [PubMed](#)
10. Jin J, *et al.* 2014. *PLoS One.* 9:104753. [PubMed](#)
11. Benner M, *et al.* 2020. *Cell Rep.* 32:108204. [PubMed](#)
12. Baguma R, *et al.* 2017. *PLoS One.* 10.1371/journal.pone.0184563. [PubMed](#)

**RRID** AB\_315454 (BioLegend Cat. No. 506804)

## Antigen Details

---

<b>Structure</b>	Acid-labile cytokine; dimer; 35-40 kD (Mammalian)
<b>Bioactivity</b>	Inhibit IFN- $\gamma$ , TNF- $\beta$ , IL-2 production by T $\text{H}$ 1 clones; inhibits macrophage-mediated IL-1, IL-6, TNF- $\alpha$ synthesis; suppress delayed type hypersensitivity response; stimulate T $\text{H}$ 2 cell response; mast cell proliferation in
<b>Cell Sources</b>	Activated CD8 <sup>+</sup> and CD4 <sup>+</sup> T cells, activated monocytes, mast cells, Ly-1 B (mouse)
<b>Cell Targets</b>	T cells, B cells, mast cells, macrophages
<b>Receptors</b>	IL-10R (CDw210)
<b>Cell Type</b>	Tregs
<b>Biology Area</b>	Cell Biology, Immunology, Neuroinflammation, Neuroscience
<b>Molecular Family</b>	Cytokines/Chemokines
<b>Antigen References</b>	<ol style="list-style-type: none"><li>1. Fitzgerald K, <i>et al.</i> Eds. 2001. <i>The Cytokine FactsBook.</i> Academic Press San Diego.</li><li>2. de Waal-Malefyt R, <i>et al.</i> 1992. <i>Curr. Opin. Immunol.</i> 4:314.</li><li>3. Howard M, <i>et al.</i> 1992. <i>Immunol. Today.</i> 13:198.</li><li>4. Quesniaux V. 1992. <i>Research Immunol.</i> 143:385.</li></ol>
<b>Regulation</b>	Production inhibited by IL-4, IL-10
<b>Gene ID</b>	<a href="#">3586</a>

## Related Protocols

---

[Surface and Intracellular Cytokine Staining for Flow Cytometry - Video](#)

[Intracellular Flow Cytometry Staining Protocol](#)



## Other Formats

---

APC anti-human IL-10, PE anti-human IL-10, Purified anti-human IL-10, PE/Dazzle™ 594 anti-human IL-10, Ultra-LEAF™ Purified anti-human IL-10

## Product Data

---



LPS-stimulated (in the presence of monensin, 18 hours) human peripheral blood mononuclear cells were surface stained with CD14 APC, then fixed with Fixation Buffer permeabilized with Permeabilization Wash Buffer and intracellularly stained with anti-human IL-10 (clone JES3-19F1) PE (top) or rat IgG2a, κ PE isotype control (bottom). Data shown was gated on monocyte population.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587